Cerus CEO and leadership

Mr. Greenman was named our President and Chief Executive Officer in April 2011. He had been Cerus' Chief Business Officer since April 2010. Previously, he was senior vice president, business development and marketing. From 2006 to 2008, he held the position of president, Cerus Europe, and prior to that, he served as vice president, business development. Prior to joining Cerus in 1995 as director of business development, he worked in various marketing and business development positions in Baxter's Biotech Division from 1991 to 1995. Mr. Greenman currently is a member of the Board of Directors of Aduro Biotech. He received his B.A.S. in Economics and Biological Sciences from Stanford University.

Laurence Corash, M.D. is Senior Vice President and Chief Scientific Officer of Cerus Corporation, which he founded in 1992. He is Professor of Laboratory Medicine at the University of California, San Francisco, where he served for 15 years as Chief of the Clinical Laboratory Hematology Service. He has published 199 original research papers in peer reviewed journals in the field of hematology and transfusion medicine. Dr. Corash graduated from New York University School of Medicine and completed Internal Medicine training at Bellevue Hospital, New York, NY. He was a Research Associate at the National Institute of Child Health and Human Development (NICHD), Bethesda, MD (1971-73) and completed training in Hematology and Hematology-Pathology at the National Institutes of Health (NIH), Clinical Center. From 1977 to 1981 he served as Assistant Chief, Hematology Service at the NIH Clinical Center. He is Board Certified in Medicine, Hematology, and Hematology-Pathology. Dr. Corash has collaborated with scientists in academic institutions and government agencies throughout the US and abroad, as well as colleagues at Cerus on research in blood cell aging and technology for inactivation of infectious pathogens in blood components, and has directed the development of technology for the inactivation of pathogens in labile blood components. Currently, he is the Principal Investigator of a contract from the US Department of Health and Human Services to complete development of the INTERCEPT Blood System for Red Blood Cells. He also leads the Convalescent Plasma for Emerging Pathogens Consortium to develop convalescent plasma for the COVID-19 pandemic. The INTERCEPT pathogen inactivation system for preparation of platelets and plasma he developed is in use by more than 200 blood centers around the world.

Vivek joined TriVascular in October 2009 as Vice President, Commercial Operations. In this role, Vivek leads Global Marketing, Sales and Business Development. Vivek joined TriVascular from Medtronic, where he spent 8 years in roles of increasing leadership responsibility. Most recently, Vivek served as the Vice President of Global Marketing for Medtronic’s EVAR franchise and helped lead them to worldwide market share leadership. In previous roles, Vivek managed the global P&L for Medtronic’s Peripheral Vascular franchise, worked as a Policy Fellow in Medtronic’s Government Affairs Office in Washington, D.C., and served as an expatriate in Hong Kong, SAR and Tokyo, Japan leading the gastroenterology and urology franchise. Vivek joined Medtronic in business development supporting the Neurological and Diabetes sector. Prior to Medtronic, Vivek worked at the Johnson & Johnson Development Corporation. Vivek began his career as a consultant with The Wilkerson Group, a healthcare focused management consultancy. Vivek holds an MBA in Healthcare Management from The Wharton School at The University of Pennsylvania and dual bachelor’s degrees in Biology and History from the University of Michigan.

Chrystal Menard is a Chief Legal Ofcr/Gen Cnsl at Cerus. She has worked as Partner at Cooley and Senior Corporate Counsel at ZYNGA INC. Chrystal attended University of Chicago and University of Colorado Boulder.

Kevin D Green is a VP:Finance/CFO at Cerus and is based in Concord, California. He has experience at MACROMEDIA, INC. and has worked as Senior Dir:Finance/Controller at Cerus, Dir:Finance & Assistant Controller at Adobe, and VP:Finance/Chief Acctg Officer at Cerus. Kevin works or has worked as MEMBER at Pricewaterhouse Coopers (PwC).

Experienced Chief Medical Officer with a demonstrated history of working in the biotechnology industry. Skilled in Transfusion Medicine, Oncology, Blood Bank, Laboratory Medicine, and Healthcare. Strong healthcare services professional with a MS focused in Health Care Management from Harvard School of Public Health.

Laurence Corash, M.D. is Senior Vice President and Chief Scientific Officer of Cerus Corporation, which he founded in 1992. He is Professor of Laboratory Medicine at the University of California, San Francisco, where he served for 15 years as Chief of the Clinical Laboratory Hematology Service. He has published 199 original research papers in peer reviewed journals in the field of hematology and transfusion medicine. Dr. Corash graduated from New York University School of Medicine and completed Internal Medicine training at Bellevue Hospital, New York, NY. He was a Research Associate at the National Institute of Child Health and Human Development (NICHD), Bethesda, MD (1971-73) and completed training in Hematology and Hematology-Pathology at the National Institutes of Health (NIH), Clinical Center. From 1977 to 1981 he served as Assistant Chief, Hematology Service at the NIH Clinical Center. He is Board Certified in Medicine, Hematology, and Hematology-Pathology. Dr. Corash has collaborated with scientists in academic institutions and government agencies throughout the US and abroad, as well as colleagues at Cerus on research in blood cell aging and technology for inactivation of infectious pathogens in blood components, and has directed the development of technology for the inactivation of pathogens in labile blood components. Currently, he is the Principal Investigator of a contract from the US Department of Health and Human Services to complete development of the INTERCEPT Blood System for Red Blood Cells. He also leads the Convalescent Plasma for Emerging Pathogens Consortium to develop convalescent plasma for the COVID-19 pandemic. The INTERCEPT pathogen inactivation system for preparation of platelets and plasma he developed is in use by more than 200 blood centers around the world.

Mr. Greenman was named our President and Chief Executive Officer in April 2011. He had been Cerus' Chief Business Officer since April 2010. Previously, he was senior vice president, business development and marketing. From 2006 to 2008, he held the position of president, Cerus Europe, and prior to that, he served as vice president, business development. Prior to joining Cerus in 1995 as director of business development, he worked in various marketing and business development positions in Baxter's Biotech Division from 1991 to 1995. Mr. Greenman currently is a member of the Board of Directors of Aduro Biotech. He received his B.A.S. in Economics and Biological Sciences from Stanford University.

Laurence Corash, M.D. is Senior Vice President and Chief Scientific Officer of Cerus Corporation, which he founded in 1992. He is Professor of Laboratory Medicine at the University of California, San Francisco, where he served for 15 years as Chief of the Clinical Laboratory Hematology Service. He has published 199 original research papers in peer reviewed journals in the field of hematology and transfusion medicine. Dr. Corash graduated from New York University School of Medicine and completed Internal Medicine training at Bellevue Hospital, New York, NY. He was a Research Associate at the National Institute of Child Health and Human Development (NICHD), Bethesda, MD (1971-73) and completed training in Hematology and Hematology-Pathology at the National Institutes of Health (NIH), Clinical Center. From 1977 to 1981 he served as Assistant Chief, Hematology Service at the NIH Clinical Center. He is Board Certified in Medicine, Hematology, and Hematology-Pathology. Dr. Corash has collaborated with scientists in academic institutions and government agencies throughout the US and abroad, as well as colleagues at Cerus on research in blood cell aging and technology for inactivation of infectious pathogens in blood components, and has directed the development of technology for the inactivation of pathogens in labile blood components. Currently, he is the Principal Investigator of a contract from the US Department of Health and Human Services to complete development of the INTERCEPT Blood System for Red Blood Cells. He also leads the Convalescent Plasma for Emerging Pathogens Consortium to develop convalescent plasma for the COVID-19 pandemic. The INTERCEPT pathogen inactivation system for preparation of platelets and plasma he developed is in use by more than 200 blood centers around the world.